Back to Search
Start Over
Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor for treating unresectable hepatocellular carcinoma.
- Source :
-
British journal of hospital medicine (London, England : 2005) [Br J Hosp Med (Lond)] 2024 Jul 30; Vol. 85 (7), pp. 1-12. Date of Electronic Publication: 2024 Jul 16. - Publication Year :
- 2024
-
Abstract
- Aims/Background The combination of lenvatinib and programmed cell death protein 1 (PD-1) inhibitor has demonstrated significant efficacy in treating unresectable hepatocellular carcinoma. Our study aimed to evaluate the safety and efficacy of triple therapy that includes hepatic arterial infusion chemotherapy, lenvatinib and PD-1 inhibitor for treating unresectable hepatocellular carcinoma. Methods Patients with a primary diagnosis of advanced hepatocellular carcinoma between June 2020 and August 2023 were included in this study. Initially, 53 patients with hepatocellular carcinoma were enrolled. Then, 13 patients were excluded based on the inclusion criteria, resulting in 40 patients included for analysis. Among them, 31 patients received triple therapy, including 16 Barcelona Clinic Liver Cancer C stage, 12 Barcelona Clinic Liver Cancer-B, and 3 Barcelona Clinic Liver Cancer-A hepatocellular carcinoma patients. The primary endpoint was the objective response rate, while the secondary endpoints included the conversion resection rate, pathological complete response rate, pathological partial response rate, and treatment-related adverse events. Results The objective response rate was 80.65% at a median follow-up of 24.5 months (range: 12.6-55.8 months). Of the 14 patients (45.2%) who underwent conversion therapy and were eligible for surgery, 7 patients underwent liver resection and the remaining 7 patients underwent liver transplantation. The median interval between the start of triple therapy and surgery was 117 days, ranging from 25 to 215 days. The pathological complete response was observed in six patients (19.4%) and the pathological partial response rate in eight patients (25.8%). All adverse events occurred in 77.4% of the patients. Conclusion In patients with unresectable hepatocellular carcinoma, the combination of hepatic arterial infusion chemotherapy, lenvatinib, and PD-1 inhibitor exhibits favourable efficacy and well tolerability, achieving a desirable pathological complete response rate while maintaining manageable drug toxicity.
- Subjects :
- Humans
Male
Female
Middle Aged
Aged
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Adult
Immune Checkpoint Inhibitors therapeutic use
Immune Checkpoint Inhibitors administration & dosage
Treatment Outcome
Hepatic Artery
Carcinoma, Hepatocellular drug therapy
Carcinoma, Hepatocellular pathology
Liver Neoplasms drug therapy
Liver Neoplasms pathology
Phenylurea Compounds therapeutic use
Phenylurea Compounds administration & dosage
Quinolines therapeutic use
Quinolines administration & dosage
Infusions, Intra-Arterial
Subjects
Details
- Language :
- English
- ISSN :
- 1750-8460
- Volume :
- 85
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- British journal of hospital medicine (London, England : 2005)
- Publication Type :
- Academic Journal
- Accession number :
- 39078898
- Full Text :
- https://doi.org/10.12968/hmed.2024.0159